Silence Therapeutics priced an upsized public offering intended to raise about $175 million, adding incremental capital for its short interfering RNA pipeline after divesiran reached a “best-case” Phase 2 outcome in a rare leukemia study. The financing size increased from the company’s earlier proposal and signals investor appetite for RNA silencing programs tied to clinical catalysts. In parallel, AbCellera moved to raise $200 million through an underwritten public offering aimed at supporting its menopause antibody program ABCL635 in ongoing clinical development. Both moves reflect the capital-intensive nature of advancing novel modalities and the reliance on market-access windows to fund late-stage execution.